From The Motley Fool · Motley Fool Transcribing · · 1m 40s
CVRx Q3 2026 Earnings Report Highlights
CVRx reports 6.1% revenue drop as Medicare reimbursement delays and physician turnover challenge growth.
In brief
CVRx reports 6.1% revenue drop as Medicare reimbursement delays and physician turnover challenge growth. CVRx reported $13.8 million Q3 revenue, a 6.1% year-over-year decline, driven by Medicare reimbursement delays and physician turnover, with full-year revenue guidance lowered to $56-$57 million. Originally reported…
Q3 Revenue
Total revenue of $13.8 million, a 6.1% decrease compared to Q3 2025.
U.S. Revenue
U.S. revenue of $13 million, a 4% decline year over year.
European Revenue
European revenue of $900,000, a 27% decline year over year.
U.S. Commercial Units
412 U.S. commercial units, down from 420 units in Q3 2025.
Gross Margin
Gross margin of 87%, consistent with 2025.
Active Implant Centers
262 U.S. active implant centers as of Sept. 30, 2026.
Medicare Approval Rate
51% Medicare Advantage approval rate for 30-day prior authorizations.
Largest Payer Approval Rate
12% approval rate for 30-day prior authorizations with largest Medicare Advantage payer.
R&D Expenses
R&D expenses of $2.7 million, a 16% decrease.
Selling, General and Administrative Expenses
SG&A expenses of $22.4 million, a 2% increase.
Operating Expenses
Operating expenses of $25.1 million for the quarter.
Net Loss
Net loss of $14.2 million, or $0.52 per share.
Cash and Cash Equivalents
Cash and cash equivalents of $58.7 million as of Sept. 30, 2026.
Full Year 2026 Revenue Guidance
Full year 2026 revenue guidance of $56 million to $57 million.
Fourth Quarter 2026 Revenue Guidance
Fourth quarter 2026 revenue guidance of $11.7 million to $12.7 million.
Cash Runway
Cash runway of at least 18 months.
What to remember
CVRx reported $13.8 million Q3 revenue, a 6.1% year-over-year decline, driven by Medicare reimbursement delays and physician turnover, with full-year revenue guidance lowered to $56-$57 million.
